The traditional pharmacological treatments for osteoporosis have various problems, such as poor pharmacokinetic properties (e.g., short half-life of salmon or eel calcitonin), frequent occurrence of adverse effects (e.g., bisphosphonates), and variability in patient compliance (Yamauchi et al., 2003; Asafo-Adjei et al., 2016; Tabatabaei-Malazy et al., 2017). This evidence concerns the gene CALCA and osteoporosis.